Nurix partners with Roche on BTK degrader bexobrutideg for up to $2.3B

Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, receiving $700 million upfront plus up to $2.3 billion in milestone payments. The partnership combines Nurix's protein degradation technology with Roche's clinical expertise to expand bexobrutideg across hematology, immunology, and neurology indications.